Theratechnologies Inc., a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, announced that it has resumed distribution of EGRIFTA SV^® (tesamorelin for injection), following correspondence from the U.S. Food and Drug Administration (FDA) that allows the Company to release two recently manufactured batches of EGRIFTA SV^®. The product is ready for immediate shipment to network pharmacies.

“We remain committed to providing EGRIFTA SV^® to people with HIV and we truly appreciate the FDA’s collaboration to get the treatment back to the patients who rely on it,” said Christian Marsolais, PhD, Senior Vice President and Chief Medical Officer at Theratechnologies.

Review of the Company’s Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025.